C5 and age-related macular degeneration: Structurally, it is composed of 39 bases, with a PEG modification at the 5’ end, a capped structure at the 3’ end, and a molecular weight of nearly 56 kDa.612 It can efficiently and specifically bind to complement C5 in patients with AMD and received FDA approval for geographic atrophy in 2023.612 In a phase II AMD study (NCT03362190), 43 subjects received monthly doses of 0.3, 1, or 2 mg of avacincaptad pegol along with 0.5 mg of Lucentis (OphthoTech Corporation).